Pharmaceutical Intermediates Smart Drugs Donepezil/nootropic@ycgmp.com

본문 바로가기


Home > Product > Pharmaceutical Intermediates Smart Drugs Donepezil/nootropic@ycgmp.com
Selling leads
Pharmaceutical Intermediates Smart Drugs Donepezil/nootropic@ycgmp.com
Posting date : May 20, 2017
Membership
Free Member Scince May 19, 2017
FOB Price
$1
Min. Order Quantity
5g
Supply Abillity
500kg/mongth
Port
HK/Shanghai
Payment Terms
T/T Bank wire transfer,Western Union,MoneyGram,Bitcoin
Package
discreet package for delivery guarantee
Keyword :
Category
Contact
Cindy Lee
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Biopharmchem
Model Number
CAS: 120014-06-4
HS-CODE
-
Package & Delivery Lead Time
Package
discreet package for delivery guarantee
Delivery Lead Time
5-7 working days
Detailed Description
Pharmaceutical Intermediates Smart Drugs Donepezil/nootropic@ycgmp.com
 
Product Name: Donepezil
CAS: 120014-06-4
MF: C24H29NO3
MW: 379.492
Purity: 99%
MP: 207℃
BP: 527.9°C at 760 mmHg
FP: 273.1°C
Density: 1.141g/cm3
Grade: Pharmaceutical Grade
Appearance: White Powder
 
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the palliative treatment of Alzheimer's disease. Common side effects include gastrointestinal upset. It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a biological half-life of about 70 hours, it can be taken once a day.
 
Function
 
Donepezil has been tested in other cognitive disorders including Lewy body dementia and vascular dementia, but it is not currently approved for these indications. Donepezil has been found to improve sleep apnea in Alzheimer's patients. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, CADASIL, and Down syndrome.
 
A 3 year NIH trial in patients with mild cognitive impairment reported that donepezil was superior to placebo in delaying rate of progression to dementia during the initial 18 months of the study but this was not sustained at 36 months. In a secondary analysis, a subgroup of individuals with the Apolipoprotein E4 genotype showed sustained benefits with donepezil throughout the study. However at this time donepezil is not indicated for prevention of dementia.
 
Recent studies suggest that Donepezil can improve speech in children with autism. The studies found that speech of autistic children who were mild to moderately affected appeared to improve from the use of Donepezil.
 
Mechanism of Action
 
Donepezil binds and reversibly inactivates the cholinesterases, thus inhibiting hydrolysis of acetylcholine. This results in an increased acetylcholine concentrations at cholinergic synapses.
 
The precise mechanism of action of donepezil in patients with Alzheimer's disease is not fully understood. Certainly Alzheimer's disease involves a substantial loss of the elements of the cholinergic system and it is generally accepted that the symptoms of Alzheimer's disease are related to this cholinergic deficit, particularly in the cerebral cortex and other areas of the brain. It is noted that the hippocampal formation plays an important role in the processes of control of attention, memory and learning. Just the severity of the loss of cholinergic neurons of the central nervous system (CNS) has been found to correlate with the severity of cognitive impairment.
 
In addition to its actions as an acetylcholinesterase inhibitor, donepezil has been found to act as a potent agonist of the σ1 receptor (Ki = 14.6 nM), and has been shown to produce specific antiamnestic effects in animals mainly via this action.
 
Side Effects
 
In clinical trials the most common adverse events leading to discontinuation were nausea, diarrhea, and vomiting. Other side effects included difficulty sleeping, muscle cramps and anorexia. Most side effects were observed in patients taking the 23 mg dose compared to 10 mg or lower doses. Side effects improved with continued use.

ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2024 ECROBOT.COM. All rights reserved.
Top